|Working from the theme “Take It to the Top,” BioNJ will bring together chief executive officers (CEO) and leaders from major biotech and pharmaceutical firms from New Jersey and beyond this fall to share their knowledge, experiences and views on the future in wide-ranging discussions with fellow executives, investors, entrepreneurs, academics and other members of the State’s diverse and ever-evolving life sciences community.
Take It to the Top, BioNJ’s first CEO Summit will be held October 4, 2013 at the Bridgewater Marriott in Bridgewater.
“New Jersey’s biopharmaceutical industry has the vision and marketplace leadership to establish our state as the Medicine Chest of the World,” said Dr. Francois Nader, President and Chief Executive Officer of NPS Pharmaceuticals and Chairman of BioNJ. “The BioNJ CEO Summit will tap into our State’s extraordinary talent with an iconic event for the life sciences industry that will be a must-attend summit for biopharma professionals throughout the region.”
Touching on some of the most important issues impacting life sciences companies today, the BioNJ CEO Summit will feature industry leaders as Keynote Speakers. Robert J. Hugin, Chairman and CEO of Celgene Corporation will provide the Luncheon Keynote. The Morning Keynote will be provided by Andre Wyss, U.S. Country Head, President of Novartis Corporation and President of Novartis Pharmaceuticals Corporation. And John F. Crowley, Chairman and CEO of Amicus Therapeutics, Inc.,and Chris Garabedian, President and CEO of Sarapeta Therapeutics, will offer Afternoon Keynotes.
Ongoing New Jersey company success stories will be showcased in Company Presentations by: Will Lewis, President and CEO of Insmed Incorporated; David Pearson, President of Thrombogenics, Inc.; and Spiro Rombotis, President and CEO of Cyclacel Pharmaceuticals, Inc.
In addition, targeted panels – Trends in Outsourcing, the Elusive IPO Window and The Billion Dollar Baby – will offer new twists and perspectives.
The growing list of speakers and moderators adding their names to the panels includes: Julie Kampf, CEO and President of JBK Associates International; James Marino, Partner at Dechert LLP; Anthony Marucci, Founder, President and CEO of Celldex Therapeutics; Paul Meister, Chairman and CEO of inVentiv Health, Inc.; Kenneth I. Moch, President and CEO of Chimerix, Inc.; Francois Nader, M.D., President and CEO of NPS Pharmaceuticals, Inc.; Lorenzo Pellegrini, Ph.D., Partner at Care Capital, LLC; Christian S. Schade, Executive Vice President and CFO of Omthera Pharmaceuticals, Inc.; Panna Sharma, President and CEO of Cancer Genetics, Inc.; Glenn Sblendorio, President and CFO of The Medicines Company; and Michael Wells, Managing Director of Princeton Biopharma Capital Partners LLC.
Registration for the event is $550 for BioNJ members and $650 for future members. To register, please visit http://www.bionj.org/ceosummit2013/home-3 or call (609) 890-3185.
A wide range of sponsorship opportunities are available; for details, please contact Kathleen Otto, Vice President of Business Development and Programs at 609-890-3185 or KOtto@BioNJ.org.